Table 3.
Distribution of CD and UC patients in relation to arthritis and their activity
| aCD/aeSpA | aCD/ieSpA | iCD/aeSpA | iCD/ieSpA | aUC/aeSpA | aUC/ieSpA | iUC/aeSpA | iUC/ieSpA | |
|---|---|---|---|---|---|---|---|---|
| Patients (N) | 5 | 15 | 0 | 14 | 4 | 16 | 0 | 6 |
| Sex (M/F) | 4/1 | 10/5 | 0 | 8/6 | 4/0 | 7/9 | – | 4/2 |
| Age | ||||||||
| Median [range] | 35 [20–61] | 27 [18–46] | – | 36.5 [18–56] | 34 [30–63] | 37.5 [23–65] | – | 65 [23–70] |
| Disease duration | ||||||||
| Median [range] | 3 [2–6] | 2 [0.2–20] | – | 2 [0.1–11] | 4.5 [1–10] | 2 [0.1–20] | – | 7.5 [0.4–30] |
| CDAI | ||||||||
| Median [range] | 200 [130–237] | 100 [12–400] | – | 75.5 [20–150] | 5.5 [4–8] | 4 [1–7] | – | 1 [0–2] |
| BASDAI | ||||||||
| Median [range] | 4.7 [1.2–5.2] | 2.4 [1.6–3.2] | – | 3 [1.8–3.8] | 4 [3.7–6.4] | 1.2 | – | 1.1 [0.8–1.4] |
| CRP | ||||||||
| Median [range] | 8.3 [6–32] | 6.8 [0.2–82.4] | – | 0.9 [0.18–27] | 10.3 [4–145] | 5.9 [0.3–14.6] | – | 0.5 [0.46–2.6] |
| Cytokines (pg/ml) | ||||||||
| IL-1α | ||||||||
| Median [range] | 3.9 [3.9–118.4] | 14.6 [3.9-250] | – | 3.9 [3.9–250] | 3.9 [3.9–3.9] | 9.1 [3.9–250] | – | 3.9 [3.9–7.63] |
| IL-1β | ||||||||
| Median [range] | 3.7 [2.5–15.3] | 4 [2.2–17.1] | – | 4.1 [2.5–27.7] | 36.4 [3.7–58] | 3.2 [1.8–244] | – | 2.3 [1.8–3.7] |
| IL-1Ra | ||||||||
| Median [range] | 21.1 [12.7–186] | 16.9 [10.6–70.8] | – | 16.9 [12.7–119.9] | 91.3 [16.9–260] | 14.8 [10.6–1,671] | – | 12.7 [12.7–16.9] |
| TNFα | ||||||||
| Median [range] | 8 [0.8–49] | 3 [0–13] | – | 4.3 [0–22.4] | 2.2 [0–10.8] | 4.3 [0–17.1] | – | 3.9 [0–5.1] |
aCD active Crohn’s disease, iCD inactive Crohn’s disease, aUC active ulcerative colitis, iUC inactive ulcerative colitis, aeSpA active enteropathic spondylarthritis, ieSpA inactive enteropathic spondylarthritis